title: Neoadjuvant pertuzumab in early HER2-positive breast cancer.
authors.affiliation: Cleveland Clinic Taussig Cancer Institute,￼Cleveland, Ohio.
authors.forename: Mikkael A
authors.initials: MA
authors.lastname: Sekeres
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D011173:Portraits as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C485206:pertuzumab